Guide · Pancreatic cancer

Pancreatic cancer: what is known about treatment paths and complementary methods

What published studies show about the main treatment paths, and about methods often offered alongside or instead of standard treatment. Each figure names its study, with a link.

The figures below are results for groups of patients in a study; they are not a prediction for any one person. This page does not recommend a treatment and does not rank clinics, and it does not compare clinics' outcomes or prices. Decisions about treatment stay with the patient and the care team.

Second-opinion services, centres and published diagnostic prices are on the pancreatic cancer page.

How strong is the evidence?

Every row below carries a grade:

A — randomised trial in pancreatic cancer
B — randomised trial in another cancer, or prospective controlled study in pancreatic cancer
C — retrospective, observational, single-arm or small phase I study
D — laboratory or animal study
E — case reports or testimonials

Small, unblinded or early-stopped trials keep their grade; the limitation is stated next to the result.

Treatment paths: what studies show

Path	What the study shows	Grade	Source
Chemotherapy (mFOLFIRINOX) before surgery, borderline resectable cancer	Chemotherapy-only arm: median overall survival 29.8 months, 18-month survival 66.7%. Across both arms of the trial (126 patients, including a chemoradiation arm): 51 (40%) reached pancreatectomy, 32 of them in the chemotherapy-only arm; 90-day mortality 2%; 27 of 48 operated patients had at least one grade 3 or higher complication (50% in the chemotherapy-only arm). The chemotherapy-only arm was scheduled for 8 cycles before surgery	A (randomised phase II)	Alliance A021501, JAMA Oncol 2022, 10.1001/jamaoncol.2022.2319; complications, Ann Surg Oncol 2024, 10.1245/s10434-024-15670-6
FOLFIRINOX first, borderline or locally advanced cancer, one high-volume centre	258 patients, FOLFIRINOX for a median of 6 cycles, 98 resected: median survival 39 months if resected vs 19 months if not; 90-day postoperative mortality 8.2%. Patients were not randomised to surgery, so the gap is not all due to surgery	C	Eur J Surg Oncol 2020, 10.1016/j.ejso.2020.02.037
Long chemotherapy before surgery (FOLFIRINOX, median 10 cycles)	Median survival 41 months, counted from the first cycle, in a highly selected group: only patients who reached surgery were included	C	Ann Surg Oncol 2024, 10.1245/s10434-024-15579-0
Declining surgery that was offered (non-metastatic cancer, US national registry 2004–2013)	Declined surgery, no treatment: median 5.1 months; declined surgery, had chemoradiotherapy: 11.2 months; had surgery: 20.5 months. Mostly before FOLFIRINOX was in use	C	Ann Surg Oncol 2018, 10.1245/s10434-018-6708-y
Ablative radiotherapy, locally advanced cancer still unresectable after chemotherapy	48 patients, single-arm phase II; radiotherapy followed by re-assessment, 13 later had surgery: 2-year survival 38% overall, 31% in those never operated on	C	JAMA Surg 2026, 10.1001/jamasurg.2026.2988
Ablative radiotherapy instead of surgery, technically resectable but unfit for surgery	25 patients, median age 80: 2-year survival 43.7%	C	JAMA Oncol 2025, 10.1001/jamaoncol.2025.0460
Maintenance olaparib after platinum chemotherapy, metastatic cancer with an inherited BRCA mutation	Longer time without progression; overall survival not significantly different (olaparib 19.0 vs placebo 19.2 months; estimated 3-year survival 33.9% vs 17.8%). After surgery, olaparib vs placebo is being tested in the APOLLO trial (NCT04858334) for BRCA1, BRCA2 or PALB2 mutations	A	POLO, J Clin Oncol 2022, 10.1200/JCO.21.01604; APOLLO, ClinicalTrials.gov
Enzymes, supplements, "detoxification" and organic diet instead of chemotherapy	55 patients with inoperable cancer, NCI-sponsored; patients chose their treatment (not randomised): median survival 4.3 months vs 14 months with gemcitabine-based chemotherapy; quality of life better with chemotherapy	B	J Clin Oncol 2010, 10.1200/JCO.2009.22.8429
Alternative medicine instead of standard treatment, other cancers (breast, prostate, lung, colorectal)	Risk of death 2.5 times higher than with conventional treatment	C	J Natl Cancer Inst 2018, 10.1093/jnci/djx145

Methods offered alongside treatment: what studies show in pancreatic cancer

Method	Best available evidence	Grade	Source
Exercise during chemotherapy before surgery	PancFit, 151 patients: walking distance improved in both the exercise and usual-care groups; no difference in quality of life or clinical outcomes between groups. A three-part programme (exercise, nutrition, psychology) during chemotherapy was feasible in 14 patients	A; C	Ann Surg 2023, 10.1097/SLA.0000000000005878; Med Sci Sports Exerc 2025, 10.1249/MSS.0000000000003931
Pancreatic enzymes (PERT) with dietary support	European guidelines: the cornerstone of treatment for exocrine insufficiency. In a UK population study, patients with pancreatic cancer who received PERT lived longer (observational)	Guideline; C	UEG J 2024, 10.1002/ueg2.12674; Pancreatology 2018, 10.1016/j.pan.2018.10.010
High-dose intravenous vitamin C	34 patients with metastatic cancer, gemcitabine + nab-paclitaxel with or without 75 g vitamin C three times weekly: median survival 16 vs 8.3 months, no added side effects, in a small unblinded trial stopped early at the interim analysis. Not tested before surgery or with FOLFIRINOX	A (small unblinded phase II, stopped early)	Redox Biol 2024, 10.1016/j.redox.2024.103375
Ketogenic diet	32 patients with metastatic cancer, chemotherapy with or without a medically supervised ketogenic diet: a trend to longer survival (13.7 vs 10.2 months), not statistically significant. A phase I study with radiation included only 2 pancreatic cancer patients; 1 withdrew because of toxicity	A (small phase II); C	Cancer 2026, 10.1002/cncr.70343; Radiat Res 2017, 10.1667/RR14668.1
Fasting or fasting-mimicking diet	No pancreatic cancer trials found. In breast cancer (131 patients) more tumour responses with chemotherapy; side effects not reduced	B (other cancer)	Nat Commun 2020, 10.1038/s41467-020-16138-3
Regional hyperthermia with chemotherapy	Single-arm phase II, 18 patients with gemcitabine: median survival 8 months (17.7 months in locally advanced disease). Retrospective series of 21 patients (hyperthermia with chemoradiotherapy) and 25 patients (hyperthermia combined with low-dose chemotherapy under induced hypoglycaemia, ketogenic diet and hyperbaric oxygen). A randomised phase II trial (HEATPAC) was registered; no randomised results found; one centre reported 9 patients treated on its protocol (feasibility only)	C	Int J Hyperthermia 2012, 10.3109/02656736.2012.695428; Surg Oncol 2021, 10.1016/j.suronc.2021.101542; Complement Med Res 2019, 10.1159/000502135; HEATPAC protocol, 10.1186/s13014-017-0923-8; 9-patient report, 10.1016/j.ctro.2021.01.008
Mistletoe extract	MISTRAL, 290 patients, placebo-controlled: no benefit in survival (7.8 vs 8.3 months) or quality of life	A (negative)	Dtsch Arztebl Int 2024, 10.3238/arztebl.m2024.0080
Dendritic-cell vaccines	Phase I, 10 patients after surgery: feasible, immune responses seen; 7 of 10 had no recurrence at a median of 25 months, with no comparison group	C	Eur J Cancer 2022, 10.1016/j.ejca.2022.03.015
Metformin (part of repurposed-drug protocols)	Randomised placebo-controlled phase II, 121 patients with advanced cancer: no survival benefit	A (negative)	Lancet Oncol 2015, 10.1016/S1470-2045(15)00027-300027-3)
Intermittent hypoxic training	No clinical studies in pancreatic cancer found. In a mouse melanoma model, sleep-apnoea-type intermittent hypoxia increased tumour growth in lean mice	D	Sleep Med 2012, 10.1016/j.sleep.2012.08.012

Clinics that offer integrative or alternative methods

Facts as each clinic publishes them on its own website, checked on 3 November 2026; nothing from news, reviews, directories or intermediaries. Clinics in alphabetical order; listing is not a recommendation. The methods are the clinic's own menu — not every patient receives each one. For each method, the grade of the best evidence in pancreatic cancer from section 4 is shown in brackets; "not reviewed" means the method is not covered in this guide. "Survival or cure claims" records only whether the clinic's site publishes such statements; none are reproduced here. Two clinics on our list could not be checked because their websites did not respond on 3 November 2026: CHIPSA Hospital (Tijuana) and Leonardis Klinik (Bad Heilbrunn).

Four clinics both name pancreatic cancer and state on their own sites that they coordinate with the patient's oncologist: Care Oncology Clinic (with the existing care team), Issels (with the patient's oncologist and family doctor, including follow-up at home), Oasis of Hope (for hyperthermia only: scheduling around outside chemotherapy or radiotherapy, when agreed with the treating oncologist) and Verita Life (stated for its dendritic-cell therapy). The links lead to each clinic's contact page.

For clinics that offer their programme instead of standard treatment ("both" or "instead" in the column on standard treatment), see section 3: what studies showed when alternative protocols were used instead of chemotherapy.

Brio-Medical Cancer Clinic · Scottsdale, Arizona, United States

Methods offered (evidence grade from the table above): Whole-body hyperthermia (C); low-dose metronomic chemotherapy (not reviewed); IV vitamin C (A, small trial), IV curcumin (not reviewed), IV mistletoe (A, negative); ozone, EBOO, photodynamic therapy (not reviewed); nutrition counselling
Pancreatic cancer named: yes
Medical oncologist on staff: not stated
Alongside or instead of standard treatment: alongside — "combines cutting-edge alternative therapies with evidence-informed conventional treatments"
Coordination with your oncologist: not stated; the site tells patients to consult their doctor before changing prescribed treatment
Published price: not published; payment for each treatment week; 7-week programme
Survival or cure claims on its site: yes

Source: brio-medical.com/pancreatic-cancer

Care Oncology Clinic · remote consultations; patients in the United States and the United Kingdom only

Methods offered (evidence grade from the table above): Repurposed-drug protocol ("metabolic pharmaceutical management"; metformin, part of such protocols: A, negative); nutrition, supplement, exercise, sleep and stress guidance; blood tests and clinician reviews
Pancreatic cancer named: yes
Medical oncologist on staff: yes (board-certified medical oncologist named)
Alongside or instead of standard treatment: alongside — "adjunctive to conventional cancer treatments"
Coordination with your oncologist: stated: care can be coordinated with the existing team; the clinic asks patients to continue full standard care
Published price: initial programme USD 1,195 / GBP 895; reviews every 8 weeks USD 995 / GBP 745; blood tests, prescriptions and medicines extra
Survival or cure claims on its site: yes

Source: careoncology.com — pancreatic cancer; pricing

Clinicum St. Georg · Bad Aibling, Germany

Methods offered (evidence grade from the table above): Conventional oncology with hyperthermia (C); micronutrient infusions, phytotherapy, nutrition therapy, traditional Chinese medicine, hydrotherapy (not reviewed); psycho-oncology, exercise and physiotherapy
Pancreatic cancer named: cancer in general
Medical oncologist on staff: yes (haematology and oncology specialist named)
Alongside or instead of standard treatment: alongside — "Standardbehandlungen der modernen Onkologie mit komplementären Therapien kombiniert" (in English: standard treatments of modern oncology combined with complementary therapies)
Coordination with your oncologist: stated: exchange with treating doctors on request; discharge letter to the treating oncologist
Published price: no self-pay cancer tariff published; usually 10 nights inpatient
Survival or cure claims on its site: no

Source: clinicum-stgeorg.de; FAQ

Gemeinschaftskrankenhaus Havelhöhe, Oncology Centre · Berlin, Germany

Methods offered (evidence grade from the table above): Surgery, chemotherapy, radiotherapy and antibody treatment, integrated with mistletoe (A, negative); anthroposophic nursing, eurythmy, rhythmic massage, art and music therapy, psycho-oncology (not reviewed); PIPAC and HIPEC (not reviewed)
Pancreatic cancer named: yes
Medical oncologist on staff: yes
Alongside or instead of standard treatment: alongside — "we combine conventional medical therapies with integrative treatments"
Coordination with your oncologist: multidisciplinary tumour meetings stated; procedure with an outside oncologist not stated
Published price: no programme tariff published (room surcharges only)
Survival or cure claims on its site: yes

Source: havelhoehe.de — pancreatic cancer

Hope4Cancer Treatment Centers · Tijuana and Cancún, Mexico

Methods offered (evidence grade from the table above): Sono-photodynamic therapy, "PDT Plus", Sunivera and DaVida bio-immunotherapy (not reviewed); nutrition plan; "detoxification", oxygenation, supplementation (not reviewed); emotional and spiritual programme
Pancreatic cancer named: yes
Medical oncologist on staff: not stated
Alongside or instead of standard treatment: both — "alongside conventional treatment or exclusively on its own"
Coordination with your oncologist: not stated
Published price: USD 45,000–60,000 for a typical 3-week programme, including lodging for patient and companion, meals and a home programme
Survival or cure claims on its site: yes

Source: hope4cancer.com — pancreatic cancer; FAQ

Immunity Therapy Center · Tijuana, Mexico

Methods offered (evidence grade from the table above): Ozone, Apatone IV, sono-photodynamic therapy (not reviewed); hyperthermia (C); on its therapy menu also insulin-potentiated therapy, laetrile (B17), HBOT, IV curcumin, LAK cells, viral vaccine (not reviewed) and dendritic-cell therapy (C)
Pancreatic cancer named: yes
Medical oncologist on staff: not stated
Alongside or instead of standard treatment: both — "both alternative and conventional treatments"; its FAQ describes options "without the need of chemotherapy and radiation"
Coordination with your oncologist: not stated
Published price: 3-week estimates: outpatient USD 18,995 (lodging separate); inpatient USD 29,995; usually 3–6 weeks
Survival or cure claims on its site: yes

Source: immunitytherapycenter.com — pancreatic cancer

IOZK — Immun-Onkologisches Zentrum Köln · Cologne, Germany

Methods offered (evidence grade from the table above): IO-VAC dendritic-cell vaccine with oncolytic virus (dendritic-cell vaccines: C); oncolytic virotherapy (not reviewed); hyperthermia (C); selected checkpoint-inhibitor and antibody treatments
Pancreatic cancer named: yes (in its list of eligible tumours)
Medical oncologist on staff: yes (haematology and medical oncology specialist named)
Alongside or instead of standard treatment: alongside — "can be combined with all conventional cancer treatments"
Coordination with your oncologist: stated: timing coordinated with chemotherapy or radiotherapy; contact with the outside oncologist not specified
Published price: cost page: laboratory EUR 6,800–8,500; vaccine EUR 23,000–26,000 per cycle, at least 2 cycles; its FAQ gives different figures (laboratory EUR 3,500–5,000; vaccine EUR 23,000–28,000)
Survival or cure claims on its site: yes

Source: iozk.de — therapy costs; FAQ

Issels (Renovo clinic) · Tijuana, Mexico

Methods offered (evidence grade from the table above): Autologous dendritic-cell vaccine (C); LAK and NK cells (not reviewed); systemic hyperthermia (C); HBOT, ozone, IV protocols (not reviewed)
Pancreatic cancer named: yes
Medical oncologist on staff: not stated
Alongside or instead of standard treatment: both — "either in combination with standard treatments or on their own"
Coordination with your oncologist: stated: works with patients' oncologists and general practitioners
Published price: not published
Survival or cure claims on its site: yes

Source: issels.com — treatment; FAQ

Klinik Arlesheim · Arlesheim, Switzerland

Methods offered (evidence grade from the table above): Chemotherapy, antibody and other systemic tumour therapies; mistletoe (A, negative); hyperthermia (C); anthroposophic medicines and nursing, eurythmy, art and music therapy (not reviewed)
Pancreatic cancer named: cancer in general
Medical oncologist on staff: yes
Alongside or instead of standard treatment: alongside — performs "alle gängigen Chemotherapien, Antikörpertherapien sowie andere systemische Tumortherapien", with anthroposophic oncology added (in English: all common chemotherapies, antibody therapies and other systemic tumour therapies)
Coordination with your oncologist: structured cooperation with the Claraspital tumour board; procedure with an outside oncologist not stated
Published price: no cancer package; foreign self-pay inpatient CHF 1,200 per day (tariff of January 2023)
Survival or cure claims on its site: yes

Source: klinik-arlesheim.ch — oncology

LDG — Laboratories Dr. Gansauge · Berg, Germany

Methods offered (evidence grade from the table above): LANEX-DC dendritic-cell therapy (dendritic-cell vaccines: C); vitamin infusions (not reviewed)
Pancreatic cancer named: yes
Medical oncologist on staff: not stated (surgical oncologist named)
Alongside or instead of standard treatment: alongside — "can often be integrated alongside conventional cancer treatments"
Coordination with your oncologist: not stated
Published price: not published
Survival or cure claims on its site: yes

Source: dendriticcelltherapybyldg.com

Oasis of Hope Hospital · Tijuana, Mexico

Methods offered (evidence grade from the table above): Dendritic-cell vaccination (C); NK, LAK and T-cell approaches (not reviewed); "metabolic therapy": ketogenic nutrition (A, small trial), fasting (B, other cancer), metformin (A, negative); high-dose IV vitamin C (A, small trial) and curcumin; ozone (not reviewed); on its treatment menu also full-body hyperthermia (C), insulin-potentiated therapy and laetrile (not reviewed)
Pancreatic cancer named: yes
Medical oncologist on staff: not stated (oncologist roles listed)
Alongside or instead of standard treatment: alongside — "combine evidence-based alternative therapies with conventional care when appropriate"
Coordination with your oncologist: stated for hyperthermia: treatment may be aligned with outside chemotherapy or radiotherapy in coordination with the treating oncologist
Published price: not published; itemised plan after a medical questionnaire; usually 2–4 weeks
Survival or cure claims on its site: yes

Source: oasisofhope.com — pancreatic cancer

Sanoviv Medical Institute · Rosarito, Mexico

Methods offered (evidence grade from the table above): Dendritic-cell (C), TIL and NK and antigen therapies (not reviewed); whole-body and regional hyperthermia (C); ozone, HBOT, methylene blue, amygdalin (B-17) (not reviewed); IV vitamin C (A, small trial); nutrition
Pancreatic cancer named: cancer in general
Medical oncologist on staff: not stated (a staff oncologist and surgical oncologist are mentioned)
Alongside or instead of standard treatment: not stated — "draw from the best alternative, complementary, and conventional therapies"
Coordination with your oncologist: not stated
Published price: USD 44,700 for a 3-week residential programme including accommodation, meals and selected treatments (programme document of 2025)
Survival or cure claims on its site: yes

Source: Sanoviv cancer programme (PDF)

Verita Life · Bangkok, Thailand

Methods offered (evidence grade from the table above): Metronomic therapy, insulin-potentiated therapy and low-dose chemotherapy, herbal and biological treatment (not reviewed); metabolic treatment; local and whole-body hyperthermia (C); NK and dendritic-cell therapies (C)
Pancreatic cancer named: yes
Medical oncologist on staff: not stated (radiation oncologists named)
Alongside or instead of standard treatment: alongside — "alongside or post medical treatments"
Coordination with your oncologist: stated: close coordination with the patient's primary oncology team
Published price: not published; written individual estimate
Survival or cure claims on its site: yes

Source: veritalife.com — pancreatic cancer

Questions to ask the care team or at a second opinion

After chemotherapy before surgery, is the tumour resectable, and which operation is planned for its location?
Do the scans show involvement or narrowing of major arteries or veins? If so, how will blood flow to the liver, stomach and spleen be preserved during surgery, and will any vein need resection or reconstruction? (A surgical series describes options chosen by the grade of narrowing of the celiac axis: Surgery 2011, 10.1016/j.surg.2011.08.012.)
Is staging laparoscopy with peritoneal washings advised before surgery? Surgeons use it mainly when imaging is indeterminate and for higher-risk patients (survey of 617 surgeons, HPB 2025, 10.1016/j.hpb.2025.12.001).
Has inherited (germline) genetic testing been done, and tumour profiling (for example BRCA1, BRCA2, PALB2, KRAS)? How do the results change the plan: platinum chemotherapy, maintenance with a PARP inhibitor, clinical trials?
How many cycles of chemotherapy are planned before surgery? (Planned 8 cycles in the A021501 trial; one centre routinely gives a median of 10.)
What is the CA 19-9 trend? Is radiotherapy being considered?
Should I be tested for exocrine insufficiency and take pancreatic enzymes? Can I see a dietitian, join an exercise or prehabilitation programme, and be checked for diabetes?
If surgery is not chosen, what non-surgical local treatment would be offered, for example ablative radiotherapy, and what outcomes would you expect compared with resection?
Which complementary treatments would the team support during chemotherapy and before surgery, and would the team coordinate with an outside clinic?
Has my case been reviewed at the hospital's multidisciplinary cancer conference (tumour board), and what did it recommend? (In Ontario, standards ask that new cancer cases be presented there: Cancer Care Ontario, multidisciplinary cancer conference standards, 2006.)

Who pays: residents of Ontario

Who pays — residents of Ontario. Specialist care in Ontario is covered by OHIP with a doctor's referral. OHIP pays for care abroad only with written prior approval from the Ministry of Health, requested by an Ontario doctor with a specialist's written confirmation, and only if the service is not experimental and either is not performed in Ontario or a delay in Ontario would risk death or irreversible harm. Without approval the patient pays everything; travel and accommodation are not covered. The ontario.ca page does not mention second opinions. Source: ontario.ca, OHIP-covered services outside Canada, updated 9 March 2026.

Studies were checked against PubMed on 3 November 2026. Back to the pancreatic cancer page.